Urine exosomes as biomarkers in bladder cancer diagnosis and prognosis: From functional roles to clinical significance

Nicholas Lee, Ashan Canagasingham, Mohit Bajaj, Ramesh Shanmugasundaram, Anthony Hutton, Joseph Bucci, Peter Graham, James Thompson and Jie Ni

Bladder cancer is one of the top ten most common cancers and top ten causes of cancer death globally. 5-year survival rates have decreased in Australia from 66% to 55% in the past three decades. The current gold standard for diagnosis is cystoscopy. However, cystoscopies are an invasive and health-resource intensive procedure which has sub-optimal sensitivity for flat lesions such as CIS (carcinoma in situ) and low specificity for differentiating inflammation from cancer - hence requiring biopsies under anesthesia. Frequent and life-long surveillance cystoscopy is required for most patients since there are high rates of progression and local recurrence in high-risk non-muscle invasive cancer (NMIBC) as well as poor outcomes associated with delayed detection of muscle-invasive bladder cancer (MIBC). There is an unmet need for a non-invasive test to provide better discrimination and risk-stratification of bladder cancer - hence requiring biopsies under anesthesia. Frequent and life-long surveillance cystoscopy is required for most patients since there are high rates of progression and local recurrence in high-risk non-muscle invasive cancer (NMIBC) as well as poor outcomes associated with delayed detection of muscle-invasive bladder cancer (MIBC). There is an unmet need for a non-invasive test to provide better discrimination and risk-stratification of bladder cancer which could aid clinicians by improving patient selection for cystoscopy; enhanced risk stratification methods may guide the frequency of surveillance cystoscopies and inform treatment choices. Exosomes, which are nano-sized extracellular vesicles containing genetic material and proteins, have been shown to have functional roles in the development and progression of bladder cancer. Exosomes have also been demonstrated to be a robust source of potential biomarkers for bladder cancer diagnosis and prognosis and may also have roles as therapeutic agents. In this review, we summarize the latest evidence of biological roles of exosomes in bladder cancer and highlight their clinical significance in bladder cancer diagnosis, surveillance and treatment.

KEYWORDS
exosome, bladder cancer, liquid biopsy, biomarker, diagnosis
Introduction

Bladder cancer was the tenth most common cancer globally, with an estimated 573,278 new diagnoses and 212,536 deaths, in 2020 (1). Bladder cancer mainly affects the elderly population, and the age-adjusted incidence of bladder cancer is significantly higher in males compared to females (34.2 vs 8.5 per 100,000) (2). Muscle-invasive bladder cancer (MIBC) invades into or past the muscularis propria, whilst cancer confined to the urothelium or lamina propria is classified as non-muscle invasive bladder cancer (NMIBC). NMIBC accounts for 80% of newly diagnosed bladder cancers and is further sub-divided into low-risk (low-grade, non-invasive papillary tumors) and high-risk (high-grade papillary tumors with/without invasion and/or CIS) groups with additional intermediate and very high-risk groups recommended by some researchers (3). NMIBC has 90% 5-year overall survival and > 95% cancer-specific survival rates (4) however the rate of recurrence and progression can be as high as 70% (4, 5) and 75% (4), respectively, in the high-risk group. Life-long surveillance is required for high-risk patients due to the high rates of recurrence which, if not detected early, can progress to MIBC by the time symptoms develop. Delayed detection of recurrence at an advanced stage (T2 or higher) is associated with worse overall survival rates (6) - with 5-year overall survival rates below 50% (7). The need for frequent surveillance cystoscopy (e.g. every 3 months for 2 years then every 6 months for 5 years then annually lifelong in high-grade NMIBC) has made bladder cancer one of the most resource-intensive malignancies to manage (8). Therapeutic options for localized bladder cancer have not significantly progressed for the past two decades, which are limited to transurethral resection of bladder tumor (TURBT) and intravesical therapy for NMIBC (9), and cystectomy/radiotherapy +/- systemic therapy for MIBC (10).

Early detection at a curable stage, accurate risk-stratification, timely treatment and adequate surveillance are key to improving long-term survival for bladder cancer patients. Cystoscopy is the current gold standard for bladder cancer diagnosis but is an invasive procedure which suffers from poor sensitivity (58-68%) for flat lesions such as CIS and non-papillary tumors (11). Urine cytology is non-invasive and has a high specificity (95%) when reported as consistent with high-grade malignancy (12), however it is more often reported as atypical or suspicious which only confers a PPV of 6-39% (13) and 47-63% respectively (14). Cytology also has poor sensitivity (37%), particularly for low-grade tumors (15). Furthermore, bladder cancer is associated with a high tumor mutation burden and multiple studies have identified a wide range of distinct molecular signatures of bladder cancer (16–22). This genetic heterogeneity presents a challenge in the use of genomics for detection and risk-stratification of bladder cancer but, if solved, genomics may improve selection for: diagnostic and surveillance cystoscopy, intra-vesical therapy, early cystectomy in high-risk NMIBC, chemo-/immuno-therapy or novel targeted therapies in MIBC and nodal/distant metastatic disease.

Exosomes are nano-sized extracellular vesicles (EVs), carrying cell-specific cargoes of proteins, lipids and nucleic acids, which are present in almost all body fluids and released by a variety of cell types by exocytosis (23). Recently, exosomes have garnered much research interest as they can transfer cargos to recipient cells - forming complex networks that connect tumor cells with tumour cells, and tumor cells with the tumor microenvironment (24). There has also been research surrounding the use of exosomes in bladder cancer diagnosis and prognosis as they may potentially be a non-invasive, economic, and convenient “liquid biopsy” tool with high sensitivity and specificity (25). Exosomes appear to be abundantly present in urine, in which the lipid bilayer protects genomic and proteomic cytoplasmic contents from degradation by urinary acidity and enzymes (26). Furthermore, since exosomes and their cargoes may provide robust information regarding the molecular landscape of bladder cancer, they may be able to stratify disease which could optimize treatment pathways and improve patient outcomes (27). In this mini-review, we discuss the biogenesis and cargoes of exosomes, summarize the latest evidence of their biological roles and highlight the clinical significance of urine exosomes in bladder cancer diagnosis, surveillance and treatment.

Exosomes

Exosomes, approximately 30-150 nm in diameter, are small EVs secreted from cells and have a bilipid membrane which protects their cargo from external influence, particularly the hostile acidic environment of urine (28). This property increases the feasibility and practicality of analyzing the cytoplasmic contents of exosome cargoes, as a source of tumor genomic and proteomic information, which may in turn provide a unique advantage over cellular and cell-free genomic tests for diagnostic use. On the interventional front, exosomes may be engineered or “repackaged” and potentially have therapeutic applications such as their use as a vector in gene therapy or a vehicle to deliver chemo-/immuno-therapeutic agents (29).

The biogenesis of exosomes occurs within cells via the endocytic pathway - with several key processes: the formation of endocytic vesicles, the generation of multi-vesicular bodies (MVBs), and the release of exosomes (30, 31). The inward budding of endosomal membranes results in the formation of intraluminal vesicles (ILVs) (32). MVBs, which are late endosomes, accumulate ILVs within their endosomal lumen (33). One fate of MVBs is their fusion with the plasma membrane and exocytosis, which releases ILVs, now termed “exosomes”, into the extracellular space (34).

Exosomes contain nucleic acids, proteins, lipids, and metabolites; however, their exact contents vary with the type
and physiological state of the parent cells (30). The ESCRT (endosomal sorting complexes required for transport) family of proteins play an important role in the unique enrichment of these exosomal cargoes compared to the parental cells (35). Furthermore, the selective sorting of exosomal cargoes has also been found to occur via novel ESCRT-independent pathways such as via tetraspanin-mediated e.g. (CD9, CD63, CD81) or lipid-raft mediated mechanisms (31). Lipids such as cholesterol, sphingomyelin, and phospholipids are enriched in exosomes and have attracted attention due to novel discoveries regarding exosomal lipid-based biomarkers (36) and their impacts on pharmacokinetics (37). It has been shown that there is also selective sorting of both non-coding RNAs (38), including microRNAs (miRNAs), long-coding RNAs (lncRNAs), and circular RNAs (circRNAs); as well as messenger RNA (mRNA) in exosomes (31). RNA-binding proteins and membrane proteins have been found to regulate the selective sorting mechanisms of miRNAs in exosomes - and it has also been demonstrated that several disease states, such as cancer and heart disease, have associated effects on miRNA expression in exosomes (39, 40).

Functional roles and clinical significance of exosomes and their cargoes in bladder cancer

Functional roles in cancer and bladder cancer

Exosomes act as intercellular messengers that ferry active biological molecules accumulated from parent cells to target cells. The transfer of genomic, transcriptomic, proteomic and metabolomic information to target cells may promote changes in metabolism and phenotype (41). In general, tumor cells produce a greater number of exosomes compared to healthy cells (42), making them an ideal candidate for cancer detection. The oncogenic properties of cargoes in tumor-derived exosomes have been shown to aid in tumor development, invasion, metastasis and drug resistance (43) (Figure 1).

In bladder cancer, exosomes have been shown to promote cell proliferation, migration, and invasion (44); angiogenesis (45); and malignant behaviors (46). Lin et al. found that exosomal miR-21 promoted bladder cancer progression by polarizing tumor-associated macrophages via PI3K/AKT pathway (47). It was also shown that bladder cancer EVs could facilitate the malignant transformation of non-malignant cells by activating endoplasmic reticulum stress-induced unfolded protein response and inflammation in vitro (48). In the tumor microenvironment, cancer-associated fibroblasts-derived exosomes could directly transport miR-148b-3p into bladder cancer cells, which was responsible for increased metastatic behaviour and drug (paclitaxel and doxorubicin) resistance in vitro and in vivo (49).

Clinical significance of exosomal cargoes as biomarkers for bladder cancer

Exosomes contain a variety of biologically functional molecules that capture a real-time snapshot of the heterogeneity of the entire tumor. In addition, exosomes are stable, abundant and accessible in almost all types of body fluids (42). Exosome biomarkers may improve the current standard of care by identifying patients with aggressive forms of bladder cancer.
cancer - allowing for optimal management and treatment decisions, reducing the frequency of surveillance, and potentially forming the basis of new treatments. Table 1 summarizes some key findings in the clinical utility of exosome cargoes in the diagnosis and prognosis of bladder cancer.

**Exosomal RNAs as biomarkers in bladder cancer**

The recent discovery of nucleic acids in urine exosomes has emerged as promising diagnostic biomarkers for bladder cancer. In a comparative study, Perez et al. evaluated the mRNA expression in five bladder cancer patients and six non-cancer patients and found that LASS2 and GALNT1 were present in cancer patients, while ARHGEF39 and FOXO3 were only present in non-cancer patients (53). Another study (n=60) carried out by Matsuzaki et al. found that urinary exosomal miR-21-5p was able to differentiate urothelial carcinoma patients than in patients with hematuria or pyuria (sensitivity, 91.5%; specificity, 76.2%) and the sensitivity even increased to 94.0% in patients with gross hematuria (51). These findings are significant as they have identified biomarkers that can distinguish which patients with hematuria should undergo a full work-up, with greater sensitivity and specificity compared to cytology.

As bladder cancer is a heterogeneous disease characterised by a high mutation burden, several studies highlighted the importance of integrated molecular profiles rather than single gene tests which may be abnormal in some tumors but not others. Using RNA sequencing, Huang et al. identified an RNA panel consisting of three mRNAs (KLHDC7B, CASP14, and PRSS1) and two lncRNAs (MIR205HG and GASS) that is able to distinguish bladder cancer patients from healthy volunteers (AUC=0.924, 95% CI, 0.875–0.974), and the expression levels of these five RNAs were correlated with clinicopathological features (57). Similarly, a study conducted by Yazarlou et al. (n=108), found that the expression levels of an exosome lncRNA panel (UCA1-201, UCA1-203, MALAT1 and LINCO0355) had high sensitivity and specificity in differentiating urothelial carcinoma from normal samples (92% sensitivity and 91.7% specificity) (52).

However, although biomarker panels have higher diagnostic performance compared to single or dual biomarkers, there are issues in their translation to clinical implementation as the cost, complexity, and convenience of the test are important factors to consider and they require multiple external validations in independent studies across a range of populations.

Exosomal biomarkers have also been researched as prognostic markers for bladder cancer but are largely in infancy. Andreu et al. demonstrated that urinary exosomal...

---

**Table 1: Clinical significance and performance of exosomal cargoes as biomarkers in bladder cancer.**

| Urine exosome biomarker/s | Biomarker type | Clinical significance | Performance | Reference |
|--------------------------|---------------|-----------------------|-------------|-----------|
| miR-21-5p                | miRNA         | Diagnosis of negative urine cytology bladder cancer. | AUC = 0.900 (95% CI, 0.875–0.974) | (50) |
| miR-6124: miR-4511 ratio | miRNA         | Discriminate hematuria from bladder cancer. | Sensitivity (in patients with gross hematuria): 94% | (51) |
| IncRNA UCA1-201           | IncRNA        | Single biomarker with diagnostic potential. | AUROC: 0.73 (vs normal samples), 0.93 (vs total controls) | (52) |
| IncRNA UCA1-201, IncRNA UCA1-203, MALAT1, LINCO0355 | IncRNA | Potential diagnostic panel. | AUC = 0.96 (95% CI, 0.875–0.974) | (52) |
| LASS2 and GALNT1, ARHGEF39 and FOXO3 | mRNA | Cancer vs non-cancer differentiation. | LASS2 and GALNT1 in cancer patients; ARHGEF39 and FOXO3 in non-cancer | (53) |
| IncRNA HYMA1, LINCO0477, LOC100506688 and OTX2-AS1 | IncRNA | Potential biomarker for high-grade MIBC. | IncRNAs enriched in high-grade MIBC vs control | (54) |
| IncRNAs (MALAT1, PCAT-1 and SPRY4-IT1) | IncRNA | Improved diagnostic value compared to urine cytology. | AUC: 0.813 (95% CI, 0.762–0.830) | (55) |
| PCAT-1 and MALAT1         | IncRNA        | Association with NMIBC recurrence-free survival. | Correlation between RFS of NMIBC with PCAT-1 and MALAT1 | (55) |
| APOA1, CDS1, FGA, FGB, FGG, HPR, and HP | Protein | Several proteins which could serve as bladder cancer grade discriminators | AUC values ranged from 0.762 to 0.830 | (56) |
| TACSTD2                  | Protein       | Potential role in bladder cancer diagnosis | AUC = 0.735 (95% CI, 0.695–0.773) | (56) |
miR-375 was a biomarker for high-grade bladder cancer while miR-146a could identify low-grade patients using a microarray platform (58). Other studies found that urinary exosomes from patients with high-grade bladder cancer were enriched in lncRNA HYMA1, LINC00477, LOC100506688, OTX2-AS1 (54) and TERC (59). Recently, Zhan et al. established that upregulation of exosomal lncRNA PCAT-1 and MALAT1 was associated with poor recurrence-free survival (RFS) of NMIBC, with PCAT-1 overexpression being an independent prognostic factor (55). These lines of evidence further support the feasibility and utility of urinary exosome biomarkers for bladder cancer risk stratification, to inform use and intensity of intra-vesical and radical treatment options for high-risk NMIBC, and to guide personalized treatment for MIBC. There is currently a large-scale prospective cohort study (n = 3000), in its recruitment stage, evaluating the clinical performance of a urine exosome-based test in the diagnosis of bladder cancer in hematuria patients, and the identification of recurrent disease in bladder cancer patients (NCT04155359).

**Exosomal proteins as biomarkers in bladder cancer**

There have been several studies that investigated the association between the urinary exosome proteome and bladder cancer. Smalley et al. (60) identified the upregulation of several proteins in urinary exosomes of bladder cancer patients compared to healthy individuals (n=9). Furthermore, five of the nine differentially expressed proteins (NRas, EPS8L1, EPS8L2, Mucin 4, and EH Domain-containing Protein 4) are implicated in the epidermal growth factor receptor (EGFR) pathway that is associated with worse prognosis in bladder cancer (61). Using quantitative proteome profiling, protein makers TPP1, TPMRSS2 and FOLR1 were consistently detected and highly upregulated in urinary exosomes derived from the bladder compared to those derived from the ureter. The study also revealed that a distinct population of exosomes released from the bladder might promote distant recurrence through metabolic rewiring, even after apparent complete downstaging (62). More recently, the same group further confirmed in 10 cT2 bladder cancer patients that despite the absence of detectable tumor, the entire bladder released exosomes that contribute to metastasis, regardless of sampling site, and highlighted the need for early radical cystectomy in cT2 bladder cancer (63).

Chen et al. (56) examined urinary exosome proteins in bladder cancer patients and identified that the concentrations of 24 proteins changed significantly compared to the control group, with AUC values ranging from 0.702 to 0.896. Moreover, they found that concentrations of TACSTD2 in urinary exosomes had 6.5-fold higher expression in bladder cancer patients compared to control patients, which has high potential as a novel biomarker for early diagnosis and prognosis for bladder cancer.

**Exosomes as therapeutic targets**

Apart from the applications in diagnosis and prognosis, novel therapeutic approaches involving exosomes may also be a possibility. Methods of altering exosome biogenesis, delivery or cell uptake could be investigated and potentially used to control the detrimental effects of tumor-derived exosomes. There are currently no studies of therapies targeting cancer-derived exosomes in bladder cancer per se, although studies have suggested that EV-targeting antibodies or antagonists showed therapeutic and chemo-/immuno-sensitizing potentials in breast (64), pancreatic (65, 66) and colorectal (67) cancers.

There is also interest in utilizing exosomes as a therapeutic vector. Due to their size, ability to cross biological barriers and autologous nature, exosomes could be packaged with pharmacological drugs or tumor-suppressive RNAs that could alter the phenotype of malignant cells (64). Early-phase clinical trials testing EV-based cancer therapy have been completed (68, 69), confirming their capacity to produce anti-tumor effects in patients, and warrant the feasibility of further large-scale investigations. Phase I clinical trials demonstrated the ability of dendritic cell-derived exosomes to exert natural killer cell effector functions in patients, however, a phase II clinical trial evaluating its effectiveness as maintenance immunotherapy on non-small cell lung cancer did not reach its primary endpoint (69). Several other clinical trials are currently underway, testing exosomes as a delivery vehicle for anti-tumor drugs (NCT01294072) or small interference RNAs (NCT03608631).

**Challenges and future perspectives**

Exosomes and their cargoes have generated increasing research interest over the last decade. Investigations have demonstrated promising results regarding their use as biomarkers in the diagnosis and risk-stratification of bladder cancer. The efficient and accurate isolation, quantification and profiling of exosomes are crucial for biomarker discovery. In the current standard workflow, these steps are performed separately. While the techniques are well-established, they are often laborious, costly and time-consuming, limiting their application in clinical settings. Recently, several "lab-on-a-chip" fluorescent (70), magneto-electrochemical (71), nanoplasmic (72) and cationic lipoplex nanoparticle (73) technologies have been developed for detection of proteins and miRNAs in exosomes from biological fluids. However, they either require pre-processed clinical specimens or involve intricate fabrications. Future research is warranted to overcome these challenges and ultimately establish the value of a single integrated platform in a clinically validated study to enable point-of-care diagnostics. It has also been demonstrated that exosomes could be used as therapeutic agents in various types of cancers. Exosomes have unique advantages to current
therapeutic agents, such as their high drug release stability, bio-compatibility and penetration of biological barriers; a greater understanding of their biological mechanisms and further clinical studies will aid in the development of exosomes for cancer therapy (74).

In the current clinical landscape for bladder cancer, there are several key areas where exosome-based biomarkers could provide benefit: (i) diagnosis; (ii) frequency of surveillance; (iii) type and intensity of intra-vesical treatment; (iv) selection for radical treatment in high-risk NMIBC; (v) selection for neo-/adjuvant chemotherapy and/or immunotherapy; and (vi) monitoring of disease progression. As stated previously, early diagnosis and personalized surveillance of bladder cancer could improve long-term survival, cost and quality of life outcomes. Additionally, from a clinical and health system perspective, the accurate stratification of lower-risk patients could reduce the need, or frequency, for cystoscopy thus reducing the burden on patients and healthcare systems.

Author contributions

NL, JT and JN conceived the project. NL, AC, MB, RS and JN prepared the initial draft. NL prepared the figure and table. AH, JB, PG and JT revised the manuscript. All authors have approved the submitted version of the manuscript.

Funding

This work was supported by Cancer Care Centre Research Trust Fund, St George Hospital.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin (2021) 71(3):209–49. doi:10.3322/caac.21660
2. Surveillance, Epidemiology, and End Results (SEER) Program. Stat database: Incidence - SEER research data 8 registries. (2019) (1975-2019) - linked to county attributes - time dependent (1990-2019) income/rurality, 1969-2020 counties, national cancer institute, DCCPS, surveillance research program. (2022).
3. Sylvester RJ, Rodriguez O, Hernandez V, Turturica D, Bauerova I, Bruins HM, et al. European Association of urology (Eau) prognostic factor risk groups for non-Muscle-Invasive bladder cancer (Nmbc) incorporating the who 2004/2016 and who 1973 classification systems for grade. An update from the eau nmbc guidelines panel. Eur Urol (2021) 79(4):480–8. doi:10.1016/j.euro.2020.12.033
4. Ravva K, Watz ME, Weissert JA, Downs TM. Predicting nonmuscle invasive bladder cancer recurrence and progression in a united states population. J Urol (2017) 198(4):824–31. doi:10.1016/j.juro.2017.04.077
5. Lu M, Chen S, Zhou Q, Wang L, Peng T, Wang G. Predicting recurrence of nonmuscle-invasive bladder cancer (Ta-T1): A study based on 477 patients. Med (Baltimore) (2019) 98(28):e16426. doi:10.1097/md.0000000000016426
6. Stein JP, Lieskovsky G, Cote R, Grossen S, Fong A-C, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol (2001) 19(3):666–75. doi:10.1200/jco.2001.19.3.666
7. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA: A Cancer J Clin (2016) 66(4):271–89. doi:10.3322/caac.21349
8. Patel VG, Oh WK, Galisky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA: A Cancer J Clin (2020) 70(5):404–23. doi:10.3322/caac.21691
9. Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. European Association of urology guidelines on non-Muscle-Invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol (2022) 81(1):75–94. doi:10.1016/j.euro.2021.08.010
10. Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, et al. European Association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines. Eur Urol (2021) 79(1):82–104. doi:10.1016/j.euro.2020.03.055
11. Schubert T, Rausch S, Fahmy O, Gakis G, Stentif. Optical improvements in the diagnosis of bladder cancer: Implications for clinical practice. Ther Adv Urol (2017) 9(11):251–60. doi:10.1177/1756287217773040
12. Renshaw AA, Gould EW. High grade urethral carcinoma in urine cytology with jet black and smooth or glassy chromatin. Cancer Cytopathol (2018) 126(1):64–8. doi:10.1002/cncy.21947
13. Tan WS, Sarpong R, Khetrapal P, Rodsny S, Mostafid H, Cresswell J, et al. Does urinary cytology have a role in haematuria investigations? BJU Int (2019) 123(1):74–81. doi:10.1111/bju.14459
14. Joudi AM, Pambuccian SE, Wojcik EM, Barkan GA. The positive predictive value of “Suspicious for high-grade urethral carcinoma” in urinary tract cytology specimens: a single-institution study of 665 cases. Cancer Cytopathol (2016) 124(11):811–9. doi:10.1002/cncy.21764
15. Lenis AT, Lee PM, Charnke K, MSHS M. Bladder cancer: A review. JAMA (2020) 324(19):1980–91. doi:10.1001/jama.2020.17598
16. Hurst CD, Platt FM, Knowles MA. Comprehensive mutation analysis of the tert promoter in bladder cancer and detection of mutations in voided urine. Eur Urol (2014) 65(2):367–9. doi:10.1016/j.eururo.2013.08.057
17. Billery C, Chapuis D, Aubriot-Lorton MH, Rocé D, Gil Diez de Medina S, Van Rhijn B, et al. Frequent Fgfr3 mutations in papillary non-invasive bladder (Pta) tumors. Am J Pathol (2001) 158(6):1955–9. doi:10.1016/s0002-9440(10)64665-2
18. Nordentoft I, Lamy P, Birkenkamp-Demtröder K, Shumansky K, Vang S, Hornbæk H, et al. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep (2014) 7(5):1569–63. doi:10.1016/j.celrep.2014.04.038
19. Solomon DA, Kim JS, Bondaaruk J, Shariat SF, Wang ZF, Elkahlon AG, et al. Frequent truncating mutations of Stag2 in bladder cancer. Nat Genet (2013) 45(12):1428–30. doi:10.1038/ng.2800
40. Liu XM, Ma L, Schekman R. Selective sorting of microRNAs into exosomes by a novel mechanism. J Cell Biol (2020) 158(3):499–511. https://doi.org/10.1083/jcb.201902.033

41. Panfoli I. Cancer exosomes in urine: A promising biomarker source. Front Oncol (2021) 11:636404. https://doi.org/10.3389/fonc.2021.636404

42. Jadli AS, Ballasy N, Edalat P, Patel VB. Inside(Sight) of tiny communicator: Exosome biology and intercellular communication. From: Fabbady Tooli L, et al. Urinary exosomal expression of long non-coding RNAs as diagnostic marker in bladder cancer. Cancers (Basel) (2014) 6:179–92. https://doi.org/10.3390/cancers6010179

43. Berrondo C, Flax J, Kucherov V, Siebert A, Osninski T, Rosenberg A, et al. Expression of the long non-coding RNA hotair correlates with disease progression in bladder cancer. Int J Oncol (2014) 45(4):1379–86. https://doi.org/10.3892/ijo.2014.2831

44. Xue M, Chen W, Xiang A, Wang R, Chen H, Pan J, et al. Hypoxic exosomes facilitate bladder tumor growth and development through transferring long non-coding RNA-Uca1. Mol Cancer (2017) 16(1):143. https://doi.org/10.1186/s12943-017-0174-8

45. Beckham CJ, Olsen J, Yin P-N, Wu C-H, Ting H-J, Hagen FK, et al. Bladder cancer exosomes contain miR-504 and facilitate cancer progression. J Urol (2014) 192(1):583–92. https://doi.org/10.1016/j.juro.2014.02.035

46. Huang C-S, Ho J-Y, Chiang J-J, Hu C-P, Yu D-S. Exosome-derived Linc00960 and Linc02470 promote the epithelial-mesenchymal transition and aggressiveness of bladder cancer cells. Cells (2020) 9(6):1419. https://doi.org/10.3390/cells9061419

47. Lee F, Yin HB, Li XY, Zhu GM, He WY, Fou X. Bladder cancer Cell –Secreted exosomal Mir-21 activates the PI3K/Akt pathway in macrophages to promote cancer progression. Int J Oncol (2020) 56(1):151–64. https://doi.org/10.3892/ijon.2019.9433

48. Wu CH, Silvers CR, Messing EM, Lee YF. Bladder cancer extracellular vesicles drive tumorigenesis by inducing the unfolded protein response in endoplasmic reticulum of nonmalignant cells. J Biol Chem (2019) 294(9):5207–18. https://doi.org/10.1074/jbc.RA118.006682

49. Pan X, Lee Y, Liu H, Wang Y, Wu H, et al. Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt/B-catenin pathway and upregulating pten. Cell Oncol (Dordr) (2021) 44(1):45–59. https://doi.org/10.1007/s13402-020-00282-2

50. Matsuzaki K, Fujita K, Jingushi K, Kawashima A, Ujiie T, Nagahara A, et al. Mir-21-5p in urinary extracellular vesicles is a novel biomarker of urinary urothelial carcinoma. OncoTARGET (2017) 8(15):24668–76. https://doi.org/10.18632/oncotarget.14969

51. Piao X-M, Jeong P, Kim Y-H, Byun YJ, Yu Y, Kang HW, et al. Urinary cell-free microRNA expression profile could discriminate bladder cancer from benign hematuria. J Cancer (2019) 10(4):380–8. https://doi.org/10.7150/jca.31849

52. Yazarlou F, Modarresi MH, Movela SJ, Khloghi Osokoei V, Motveesal E, et al. Urinary extrosomal expression of long non-coding RNAs as diagnostic marker in bladder cancer. Cancer Manage Res (2018) 10:6357–65. https://doi.org/10.2147/cmr.s168108

53. Perez A, Loizaga A, Arcoo R, Lacasa I, Rabade A, Zorrozua K, et al. A pilot study on the potential of RNA-sequenced urinary vesicles as suitable non-invasive source for diagnostic purposes in bladder cancer. Cancers (Basel) (2014) 6(4):179–92. https://doi.org/10.3390/cancers6040179

54. Berrondo C, Flax J, Kucherov V, Siebert A, Osninski T, Rosenberg A, et al. Expression of the long non-coding RNA hotair correlates with disease progression in bladder cancer and is contained in bladder cancer patient urinary exosomes. PLoS One (2016) 11(1):e0147236. https://doi.org/10.1371/journal.pone.0147236

55. Zhan Y, Du L, Wang L, Jiang X, Zhang S, Li J, et al. Expression signature of long non-coding RNA-ciras in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer. Mol Cancer (2018) 17(1):42. https://doi.org/10.1186/s12943-018-0803-y

56. Chen C-L, Lai Y-F, Tang P, Chien KY, Yu J-S, Tsai C-H, et al. and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. J Proteome Res (2012) 11(31):5611–29. https://doi.org/10.1021/pr3008732

57. Huang H, Du J, Lin B, Pang L, Duan N, Huang C, et al. Combination of urine long non-coding RNAs and IncRNas as novel diagnostic biomarkers for bladder cancer. Front Oncol (2021) 11:667212. https://doi.org/10.3389/fonc.2021.667212

58. Andrea Z, Otta Oshiro R, Redruello A, Lopez-Martín S, Gutierrez-Vazquez C, Morato E, et al. Extracellular vesicles as a source for non-invasive biomarkers in bladder cancer progression. Eur J Pharm Sci (2017) 98:70–80. https://doi.org/10.1016/j.ejps.2016.10.008

59. Chen C, Shang A, Sun Z, Gao Y, Huang J, Ping Y, et al. Urinary extrosomal long noncoding RNA as a noninvasive diagnostic and prognostic biomarker for bladder urothelial carcinoma. J Immunol (2022) 2022:9838808. https://doi.org/10.1155/2022/9838808

60. Smalley DM, Sherman NE, Nelson K, Theodorescu D. Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J Proteome Res (2008) 7(5):2088–96. https://doi.org/10.1021/pr070775x

61. Colquhoun AJ, Mollen JR. Epidermal growth factor receptor and bladder cancer. Postgrad Med J (2002) 78(924):584–9. https://doi.org/10.1136/pmj.78.924.584

62. Hilfbrunner S, Mints M, Elldt M, Rosenblatt R, Holmström B, Almadari F, et al. Urinary exosomes from bladder cancer patients show a residual cancer phenotype despite complete pathological downstaging. Sci Rep (2020) 10(1):142. https://doi.org/10.1038/s41598-020-62753-x

63. Elldt M, Mints M, Hilfbrunner S, Ladjevardi S, Almadari F, Johansson M, et al. Proteomic profiling of tissue exosomes indicates continuous release of malignant exosomes in urinary bladder cancer patients, even with pathologically undetectable tumors. Cancers (Basel) (2021) 13(13):3242. https://doi.org/10.3390/cancers13133242
64. Tong Y, Liu X, Xia D, Peng E, Yang X, Liu H, et al. Biological roles and clinical significance of exosome-derived noncoding rnas in bladder cancer. *Front Oncol* (2021) 11:704703. doi: 10.3389/fonc.2021.704703

65. Kimura H, Yamamoto H, Harada T, Fumoto K, Osugi Y, Sada R, et al. Ckap4, a Dkk1 receptor, is a biomarker in exosomes derived from pancreatic cancer and a molecular target for therapy. *Clin Cancer Res* (2019) 25(6):1936–47. doi: 10.1158/1078-0432.Ccr-18-2124

66. Mikamori M, Yamada D, Eguchi H, Hasegawa S, Kishimoto T, Tomimaru Y, et al. Microrna-155 controls exosome synthesis and promotes gemcitabine resistance in pancreatic ductal adenocarcinoma. *Sci Rep* (2017) 7:42339. doi: 10.1038/srep42339

67. Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, et al. Suppression of exosomal pd-L1 induces systemic anti-tumor immunity and memory. *Cell* (2019) 177(2):414–27.e13. doi: 10.1016/j.cell.2019.02.016

68. Escudier B, Dorval T, Chaput N, André F, Caby MP, Novault S, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (Dc) derived-exosomes: Results of the first phase 1 clinical trial. *J Trans Med* (2005) 3(1):10. doi: 10.1186/1479-5876-3-10

69. Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in nacl. *Oncoimmunology* (2016) 5(4):e1071008. doi: 10.1080/2162402x.2015.1071008

70. Jin Y, Du N, Huang Y, Shen W, Tan Y, Chen YZ, et al. Fluorescence analysis of circulating exosomes for breast cancer diagnosis using a sensor array and deep learning. *ACS Sens* (2022) 7(5):1524–32. doi: 10.1021/acssensors.2c00259

71. Jeong S, Park J, Pathania D, Castro CM, Weissleder R, Lee H. Integrated magneto-electrochemical sensor for exosome analysis. *ACS Nano* (2016) 10(2):1802–9. doi: 10.1021/acsnano.5b07584

72. Im H, Shao H, Park YI, Peterson VM, Castro CM, Weissleder R, et al. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. *Nat Biotechnol* (2014) 32(5):490–5. doi: 10.1038/nbt.2886

73. Liu C, Kannisto E, Yu G, Yang Y, Reid ME, Patnaik SK, et al. Non-invasive detection of exosomal micrornas Via tethered cationic lipoplex nanoparticles (Tcln) biosipch for lung cancer early detection. *Front Genet* (2020) 11:258. doi: 10.3389/fgene.2020.00258

74. Kim H, Jang H, Cho H, Choi J, Hwang KY, Choi Y, et al. Recent advances in exosome-based drug delivery for cancer therapy. *Cancers (Basel)* (2021) 13(17):4435. doi: 10.3390/cancers13174435